Measurement of Intratumor Heterogeneity and Its Changing Pattern to Predict Response and Recurrence Risk After Neoadjuvant Chemotherapy in Breast Cancer
Open Access
- 7 February 2025
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 32 (2) , 93
Abstract
The heterogeneity of breast tumors might reflect biological complexity and provide prediction clues for the sensitivity of treatment. This study aimed to construct a model based on tumor heterogeneity in magnetic resonance imaging (MRI) for predicting the pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). This retrospective study involved 217 patients with biopsy-confirmed invasive breast cancer who underwent MR before and after NAC. Patients were randomly divided into the training cohort and the validation cohort at a 1:1 ratio. MR images were processed by algorithms to quantify the heterogeneity of tumors. Models incorporating heterogeneity and clinical characteristics were constructed to predict pCR. The patterns of heterogeneity variation during NAC were classified into four categories abbreviated as the heterogeneity high-keep group (H_keep group), heterogeneity low-keep group (L_keep group), heterogeneity rising group, and decrease group. The average heterogeneity in patients achieving pCR was significantly lower than in those who did not (p = 0.029). Lower heterogeneity was independently associated with pCR (OR, 0.401 [95%CI: 0.21, 0.76]; p = 0.007). The model combining heterogeneity and clinical characteristics demonstrated improved specificity (True Negative Rate 0.857 vs. 0.698) and accuracy (Accuracy 0.828 vs. 0.753) compared to the clinical model. Survival outcomes were best for the L_keep group and worst for the rising group (Log-rank p = 0.031). Patients with increased heterogeneity exhibited a higher risk of recurrence approaching two years post-surgery, particularly within the non-pCR population. The quantified heterogeneity of breast cancer in MRI offers a non-invasive method for predicting pCR to NAC and evaluating the implementation of precision medicine.Keywords
Funding Information
- Shanghai Rising-Star Program (22QC1400200, 82173115, 82103695, 202340085, 20DZ2201600, PYIII20-09, RJPY-LX-002)
- National Natural Science Foundation of China (22QC1400200, 82173115, 82103695, 202340085, 20DZ2201600, PYIII20-09, RJPY-LX-002)
- Shanghai Municipal Health Commission Health Industry Clinical Research Special Project (22QC1400200, 82173115, 82103695, 202340085, 20DZ2201600, PYIII20-09, RJPY-LX-002)
- Science and Technology Commission of Shanghai Municipality (22QC1400200, 82173115, 82103695, 202340085, 20DZ2201600, PYIII20-09, RJPY-LX-002)
- Nurturing Fund of Renji Hospital (22QC1400200, 82173115, 82103695, 202340085, 20DZ2201600, PYIII20-09, RJPY-LX-002)
This publication has 23 references indexed in Scilit:
- AI‐based intra‐tumor heterogeneity score of Ki67 expression as a prognostic marker for early‐stage ER+/HER2− breast cancerThe Journal of Pathology: Clinical Research, 2023
- Photoacoustic Computed Tomography of Breast Cancer in Response to Neoadjuvant ChemotherapyAdvanced Science, 2021
- Intratumor Heterogeneity: The Rosetta Stone of Therapy ResistanceCancer Cell, 2020
- Fibrosis and cancer: A strained relationshipBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2020
- Lineage plasticity in cancer: a shared pathway of therapeutic resistanceNature Reviews Clinical Oncology, 2020
- Turning foes to friends: targeting cancer-associated fibroblastsNature Reviews Drug Discovery, 2018
- Neoadjuvant chemotherapy for early breast cancerThe Lancet Oncology, 2018
- Tumour heterogeneity and resistance to cancer therapiesNature Reviews Clinical Oncology, 2017
- Adjuvant Capecitabine for Breast Cancer after Preoperative ChemotherapyNew England Journal of Medicine, 2017
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012